October 05, 2011

FDA Issues New Warnings on Use of Simvastatin

Some days back, I was online reading up stuff on Medscape and I came across a very interesting commentary. It was written by Dr. Sandra Fryhofer in relation to the current raging simvastatin saga and her review of the FDA's latest warnings about this popular statin. I am not going to pre-empt her. I share her thoughts here because I found them quite illuminating. Happy reading!

On June 8, 2011, the United State's Food and Drug Administration (FDA) released new warnings about the dangers of high-dose simvastatin, which affects many people. The FDA also issued new warnings about its dosing and drug interactions. This article calls our attention to this FDA's warning.

Simvastatin, a popular statin, is a generic. It is quite popular and on all the pharmacy plans. Besides, the price point is right and prescribing is hassle free. In 2010, an estimated 2.1 million patients, in the US alone, were prescribed a product containing 80 mg simvastatin. Can you imagine how many would have been on it worldwide?

The highlights of the warnings:

Restrictions for 80-mg simvastatin
  • Avoid prescribing 80-mg simvastatin because of the high risk for myopathy.
  • 80-mg simvastatin is satisfactory if the patient has been on it for a year with no evidence of myopathy.
Restrictions for intermediate- and low-dose simvastatin
  • No more than 20 mg for patients taking amlodipine and ranolazine
  • No more than 10 mg for patients on amiodarone, verapamil, and diltiazem
Restrictions for simvastatin at any dose
  • The FDA has mandated drug-labeling changes warning that simvastatin is contraindicated in patients on gemfibrozil, certain antifungal medications (itraconazole, ketoconazole, posaconazole), certain antibiotics (erythromycin, clarithromycin, telithromycin) as well as HIV protease inhibitors, nefazodone, cyclosporine, and danazol.
The information on adverse effects with simvastatin are not new. In 2004, when the A to Z trial was published in JAMA, an editorial expressed concerns about increased rates of myopathy in patients on simvastatin. The most recent study to cast dispersions on simvastatin was SEARCH, published in The Lancet in 2010. It linked simvastatin 80-mg doses to increased risk for myopathy.

So why didn't the FDA act sooner? That's not clear, but the word is out now.

Simvastatin problems are public property. Patients know about them and depend on doctors to clear up their medication regimens. Not all statins are created equal and the least expensive drug may not necessarily be the best for your patient.

The above article is reproduced from material entitled 'Clarifying Simvastatin Warnings -- It's Not Just 80 mg' by Medscape Internal Medicine. Retrieved 5.10.2011 from here. Note: Materials may be edited for content and length.

No comments:

Post a Comment

Got something to say? We appreciate your comments: